{"prompt": "['EudraCT Number 2019-002880-82, IRAS Number 1003208', '9.2 Procedures for Recording and Reporting Adverse Events', 'The Medicines for Human Use (Clinical Trials) Regulations 2004 and Amended', 'Regulations 2006 gives the following definitions:', 'Adverse Event (AE): Any untoward medical occurrence in a subject to whom a', 'medicinal product has been administered including occurrences which are not necessarily', 'caused by or related to that product.', 'Note 1: This definition includes events related to the investigational medical device', 'or the comparator.', 'Note 2: This definition includes events related to the procedures involved.', 'Adverse Reaction (AR): Any untoward and unintended response in a subject to an', 'investigational medicinal product which is related to any dose administered to that subject.', 'Unexpected Adverse Reaction (UAR): An adverse reaction the nature and', 'severity of which is not consistent with the information about the medicinal product in', 'question set out in the summary of product characteristics (SmPC) for metformin', 'and UDCA', 'Serious adverse Event (SAE), Serious Adverse Reaction (SAR) or Unexpected', 'Serious Adverse Reaction (USAR): Any adverse event, adverse reaction or unexpected', 'adverse reaction, respectively, that', 'Results in death (including neonatal);', 'Is life-threatening;', 'Required hospitalisation or prolongation of existing hospitalisation;', 'Results in persistent or significant disability or incapacity;', 'Consists of a congenital anomaly or birth defect.', 'Important Medical Events (IME)', 'Events that may not be immediately life-threatening or result in death or', 'hospitalisation but may jeopardise the patient or may require intervention to prevent one', 'of the other outcomes listed in the definition above should also be considered serious.', '9.2.1 Reporting Responsibilities', \"KCL & GSTFT have delegated the delivery of the Sponsor's responsibility for\", 'Pharmacovigilance (as defined in Regulation 5 of the Medicines for Human Use (Clinical', \"Trials) Regulations 2004 to the King's Health Partners Clinical Trials Office (KHP-CTO).\", 'All Adverse Events will be recorded in the medical notes.', 'All SAEs, SARs and SUSARs (excepting those specified in this protocol as not', 'requiring reporting) will be reported immediately (and certainly no later than 24hrs) by the', 'Investigator to the KHP-CTO and CI for review in accordance with the current', 'Pharmacovigilance Policy, and subsequently recorded in the eCRF. All SAEs will be', 'reported using MedDRA coding, in liaison with the study CRA.', 'GUARD protocol V1.0 11Mar20', 'Page 29 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', 'The KHP-CTO will report SUSARs to the regulatory authorities (MHRA, competent', 'authorities of other EEA (European Economic Area) states in which the trial is taking', 'place. The Chief Investigator will report to the relevant Ethics Committee. Reporting', 'timelines are as follows:', '- SUSARs which are fatal or life-threatening must be reported not later than 7 days', 'after the sponsor is first aware of the reaction. Any additional relevant information must', 'be reported within a further 8 days.', '- SUSARs that are not fatal or life-threatening must be reported within 15 days of', 'the sponsor first becoming aware of the reaction.', '- The Chief Investigator and KHP-CTO (on behalf of the co-sponsors), will submit', 'a Development Safety Update Report (DSUR) relating to this trial IMP, to the MHRA and', 'REC annually.', '9.2.2 Definition of causality', 'The assignment of the causality should be made by the investigator responsible for', 'the care of the participant as: definitely, likely, possibly, unlikely, not related or related to', 'other study procedure.', 'An AE whose causal relationship to the study drug or study procedure is assessed', 'by the investigator as \"possibly\", \"likely\" or \"definitely\" is an Adverse Drug Reaction. All', 'events judged by the investigator to be \"possibly\", \"likely\" or \"definitely\" related to the', 'therapy or study procedure, graded as serious and unexpected should be reported as a', 'SUSAR.', '9.2.3 Severity', 'Regardless of the classification of an AE as serious or not, its severity must be', 'assessed according to medical criteria alone using the following categories:', 'Mild: does not interfere with routine activities', 'Moderate: interferes with routine activities', 'Severe: very difficult or impossible to perform routine activities', '9.2.4 Expectedness', 'If there is at least a possible involvement of the trial medications, the investigator and', 'sponsor must assess the expectedness of the event. An unexpected adverse reaction is', 'one that is not reported in the current SPC, or one that is more frequently reported or more', 'severe than previously reported. See SPC for a list of expected toxicities associated with', 'the drugs being used in this trial. If a SAR is assessed as being unexpected, it becomes a', 'SUSAR and it must be reported to the competent authority by the sponsor.', '9.2.5 Adverse events that do not require reporting', 'All adverse events will be reported from baseline until discharge from hospital for', 'mother and infant.', 'GUARD protocol V1.0 11Mar20', 'Page 30 of 53']\n\n###\n\n", "completion": "END"}